MedPath

Study on Treatment for Patients With Symptomatic Oral Lichen Planus

Not Applicable
Completed
Conditions
Lichen Planus, Oral
Interventions
Drug: Oral lichen clinical Healing evaluation
Registration Number
NCT04718311
Lead Sponsor
University of Catania
Brief Summary

The primary objective of this study was to compare the therapeutic efficacy of Tacrolimus gel versus an anti-inflammatory mouthwash in an oral solution for the management of patients suffering from symptomatic OLP. The secondary objective was to analyze which one of the two treatments induced a greater risk of developing side effects.

Detailed Description

Thirty nine patients were assigned, through a randomized design, to receive tacrolimus ointment 0.1% or a mouthwash composed of calcium hydroxide 10%, hyaluronic acid 0,3%, umbelliferone and oligomeric proanthocyanidins, or an anti-inflammatory mouthwash (mouthwash which contains calcium hydroxide, hyaluronic acid, Umbelliferone and Oligomeric Proanthocyanidins) for 3-months. At baseline (T0) and after 3 months (T1), patients were subjected to clinical and oral assessments and were evaluated for the symptoms (Numerical Pain Scale, NRS score) and signs (Thongprasom's score) of OLP. Data were calculated using T-test for the dependent variable, Wilcoxon test and Mann-Witney u test.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
60
Inclusion Criteria
  • age ≥ 18 years;
  • clinical diagnosis and histological diagnosis of OLP on the basis of WHO criteria;
  • presence of symptoms related to OLP.
Exclusion Criteria
  • presence of systemic conditions that may have affected the study results;
  • state of pregnancy or breastfeeding;
  • histological signs of dysplasia;
  • drugs inducing a lichen response (ACE-inhibitors, β-blockers, etc.);
  • treatment of OLP in the six months prior to the start of the programme;
  • presence of extraoral lesions (genital, skin and other)
  • history of previous immunodeficiency or HIV seropositivity;
  • previous allogeneic bone marrow transplantation;
  • presence of systemic lupus erythematosus or other autoimmune diseases.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Tacrolimus treatmentOral lichen clinical Healing evaluationApply a small amount (about 1 teaspoon) of medication to the lesions, twice a day after brushing the teeth, with a soft bristle toothbrush or with a finger (covered with a well-fitting glove).
Anti-inflammatory mouthwashOral lichen clinical Healing evaluationAnti-inflammatory mouthwash In patients of the anti-inflammatory group, the mouthwash was used pure and without dilution at a dosage of 20 ml 3 times a day, immediately after normal daily oral hygiene was prescribed. It contains calcium hydroxide, hyaluronic acid, Umbelliferone and Oligomeric Proanthocyanidins. Patients were instructed to rinse for at least 5 minutes over the entire oral mucosa, with particular emphasis on the regions where the lesions are located.
Primary Outcome Measures
NameTimeMethod
Clinical Mucosal healing180 days

Patients clinically were evaluated using the scale used by Thongprasom et al. as reference. This gives a score that varies from 0 to 5, using a millimetre reference: 0, in the absence of lesions; 1, in the presence of hyperkeratosis streaks; 2, in the presence of an atrophic area less than 1 mm2; 3, in the presence of an atrophic area greater than

1 mm2; 4, in the presence of an erosive area less than 1 mm2; 5, in the presence of an erosive area greater than 1 mm2. In the presence of multiple injuries, the value has been calculated by summing the values of each injury.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

University of Catania

🇮🇹

Catania, CT, Italy

© Copyright 2025. All Rights Reserved by MedPath